You are here

Article Text

Article menu
Download PDFPDF
Section 5: Patient safety and quality assurance
5PSQ-090 Lack of iso-appearance in dispensed antipsychotics in patients with schizophrenia
  1. U Lertxundi1,
  2. B Corcostegui2,
  3. S Domingo-Echaburu3,
  4. O Ibarra4,
  5. B García-Tovar1,
  6. G Mentxaka5,
  7. R Hernández6,
  8. J Medrano7
  1. 1Araba’s Mental Health Network, Pharmacy, Vitoria-Gasteiz, Spain
  2. 2Bizkaia Mental Health Network, Pharmacy, Bermeo, Spain
  3. 3Alto Deba Integrated Health Care, Pharmacy, Arrasate, Spain
  4. 4Uribe Kosta Integrated Health Care, Pharmacy, Urduliz, Spain
  5. 5Osakidetza Central Services, Informatics, Vitoria-Gasteiz, Spain
  6. 6Araba Mental Health Network, Internal Medicine, Vitoria-Gasteiz, Spain
  7. 7Bizkaia Mental Health Network, Psychiatry, Portugalete, Spain

Abstract

Background The main factor involved in the stability and improvement of patients with schizophrenia is adherence to antipsychotic treatment. Disease-related factors, patient-related factors, environmental factors and treatment-related factors have all been related to non-adherence. In this sense, several studies have shown that changes in the aspect of a pharmaceutical drug (lack of iso-appearance) can lead to poorer adherence in chronic diseases. In the context of schizophrenia, the prevalence of lack of iso-appearance in prescribed antipsychotics has been scantily studied.

Purpose To measure the proportion of patients affected by lack of iso-appearance in prescribed antipsychotics.

Material and methods To conduct this study, we linked information from different administrative healthcare databases from the Basque Country. We obtained data about patients with a diagnostic code of schizophrenia (F20*) by ICD-10 who attended in any of the public mental healthcare networks from 2 June 2016 to 2 June 2017. Patients admitted to any acute care hospital during the study period were discarded.

We measured the number of different brands of each antipsychotic dispensed to patients during the study period. We also calculated the proportion of patients that were affected by this issue globally and within each individual antipsychotic.

Results We identified 4810 different patients with schizophrenia during the study period. Different brands of the same antipsychotic were dispensed to 8.5% of patients (409/4,810). Quetiapine was the most frequently implicated drug, followed by ziprasidone and olanzapine. In the 409 affected patients, the mean number of different antipsychotic brands dispensed per patient was 1.73.

Conclusion As far as we are aware, our study is the first one to systematically measure lack of iso-appearance of prescribed antipsychotics in a large population of schizophrenic patients. The proportion of patients to whom different brands of the same antipsychotics were dispensed was lower than expected, with only 8.5% of the patients undergoing this problem. Interestingly, different brands were dispensed to almost a quarter of patients on quetiapine

References and/or Acknowledgements This project has been supported by BIOEF Basque Foundation for Health Research and Innovation

No conflict of interest

http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.443

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.